OptimizeRx (OPRX) EBITDA (2010 - 2026)

OptimizeRx (OPRX) has 17 years of EBITDA data on file, last reported at $396000.0 in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 118.84% year-over-year to $396000.0; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (up 231.77% YoY), and the FY2025 full-year result was $11.7 million, up 185.31% from the prior year.
• EBITDA eased to $396000.0 in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.6 million in Q4 2025 to a low of -$10.9 million in Q4 2023.
• A 5-year average of -$2.4 million and a median of -$3.7 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 9937.02% in 2022 and jumped 185.06% in 2025, its largest moves.
• Tracing OPRX's EBITDA over 5 years: stood at -$864348.0 in 2022, then plunged by 1161.41% to -$10.9 million in 2023, then surged by 133.33% to $3.6 million in 2024, then soared by 135.8% to $8.6 million in 2025, then sank by 95.38% to $396000.0 in 2026.
• Business Quant data shows OPRX's EBITDA at $396000.0 in Q1 2026, $8.6 million in Q4 2025, and $2.0 million in Q3 2025.